Current Rating and Its Significance
MarketsMOJO’s 'Sell' rating for Poly Medicure Ltd indicates a cautious stance towards the stock, suggesting that investors may want to consider reducing their exposure or avoiding new purchases at this time. This rating reflects a comprehensive evaluation of the company’s quality, valuation, financial trend, and technical outlook. While the rating was revised on 11 February 2026, the following analysis is based on the latest available data as of 06 March 2026, ensuring that investors receive the most relevant information for decision-making.
Quality Assessment
As of 06 March 2026, Poly Medicure Ltd holds a 'good' quality grade. This assessment is grounded in the company’s operational performance and profitability metrics. Despite some recent challenges, the firm has demonstrated a reasonable level of operational efficiency over the medium term. However, the quality grade does not fully offset concerns arising from other parameters, particularly financial trends and valuation.
Valuation Considerations
The stock is currently classified as 'expensive' in terms of valuation. With a price-to-book value of 4.7 and a return on equity (ROE) of 12.4%, Poly Medicure Ltd trades at a premium relative to its book value. Although this premium is somewhat justified by the company’s profitability, it remains elevated compared to peer averages. The PEG ratio stands at 3.3, indicating that the stock’s price growth expectations are high relative to its earnings growth. This expensive valuation suggests limited upside potential and increased risk for investors seeking value opportunities.
Financial Trend Analysis
The financial trend for Poly Medicure Ltd is currently negative. The latest quarterly results for December 2025 reveal a decline in profit after tax (PAT) to ₹75.86 crores, representing an 11.0% fall. Additionally, the operating profit to net sales ratio has dropped to 22.52%, the lowest recorded in recent quarters. The debtors turnover ratio is also at a low of 4.02 times, signalling potential inefficiencies in receivables management. Over the past five years, operating profit has grown at an annual rate of 17.77%, which is modest but insufficient to offset recent negative trends. These factors collectively contribute to the cautious financial outlook reflected in the current rating.
Technical Outlook
From a technical perspective, the stock is rated as 'bearish'. Price action over recent months has been weak, with the stock delivering a 40.84% loss over the past year. Shorter-term returns also reflect this downtrend, with a 3-month decline of 28.00% and a 6-month fall of 33.00%. The stock’s year-to-date performance is down 22.98%, underperforming broader market indices such as the BSE500. This bearish technical stance suggests that momentum remains negative, and investors should be cautious about potential further declines.
Performance Summary as of 06 March 2026
Currently, Poly Medicure Ltd’s stock shows a mixed but predominantly negative performance profile. While the company has managed to increase profits by 11.9% over the past year, this has not translated into positive returns for shareholders, as the stock price has declined sharply. The stock’s underperformance relative to the BSE500 index over one, three, and even longer-term periods highlights challenges in both market sentiment and operational execution. Investors should weigh these factors carefully when considering their portfolio allocations.
Implications for Investors
The 'Sell' rating from MarketsMOJO serves as a signal for investors to exercise caution. It suggests that the stock may face continued headwinds due to its expensive valuation, deteriorating financial trends, and weak technical momentum. While the company’s quality remains decent, it is not sufficient to outweigh the risks identified. Investors looking for stable or growth-oriented healthcare services stocks might consider alternatives with stronger fundamentals and more attractive valuations.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Sector and Market Context
Poly Medicure Ltd operates within the healthcare services sector, a space that has seen varied performance across different companies. While healthcare remains a critical and growing industry, individual stock performance can diverge significantly based on company-specific factors. The smallcap status of Poly Medicure Ltd adds an additional layer of volatility and risk, as smaller companies often face greater challenges in sustaining growth and managing market expectations.
Long-Term Growth and Profitability
The company’s long-term growth has been modest, with operating profit increasing at an annual rate of 17.77% over the last five years. However, recent quarterly results indicate a slowdown, with profitability metrics weakening. The decline in PAT and operating margins suggests that the company is facing operational pressures, which may stem from competitive dynamics, cost pressures, or market conditions. These factors contribute to the negative financial grade and reinforce the cautious stance reflected in the current rating.
Stock Returns and Relative Performance
As of 06 March 2026, the stock’s returns have been disappointing. The 1-year return of -40.84% significantly underperforms the broader market indices, including the BSE500. The negative returns extend across multiple time frames, with a 3-month loss of 28.00% and a 6-month decline of 33.00%. Even the year-to-date return of -22.98% points to ongoing challenges in regaining investor confidence. This sustained underperformance highlights the importance of the 'Sell' rating as a reflection of current market realities.
Conclusion
In summary, Poly Medicure Ltd’s 'Sell' rating by MarketsMOJO, last updated on 11 February 2026, is supported by a combination of factors including expensive valuation, negative financial trends, and bearish technical signals. While the company maintains a good quality grade, this is insufficient to counterbalance the risks identified. Investors should consider these insights carefully and monitor the stock’s performance closely, particularly in light of the challenging market environment and sector dynamics as of 06 March 2026.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
